Cannabinoid regulation of angiotensin II-induced calcium signaling in striatal neurons
Calcium ion (Ca<sup>2+</sup>) homeostasis is crucial for neuron function and neurotransmission. This study focused on the actions mediated by the CB<sub>1</sub> receptor (CB<sub>1</sub>R), the most abundant G protein-coupled receptor (GPCR) in central nervous system (CNS) neurons, over by the AT<sub>1</sub>R, which is one of the few G protein-coupled CNS receptors able to regulate cytoplasmic Ca<sup>2+</sup> levels. A functional interaction suggesting a direct association between these receptors was detected. AT<sub>1</sub>-CB<sub>1</sub> receptor heteromers (AT<sub>1</sub>CB<sub>1</sub>Hets) were identified in HEK-293T cells by bioluminescence resonance energy transfer (BRET<sup>2</sup>). Functional interactions within the AT<sub>1</sub>-CB<sub>1</sub> complex and their potential relevance in Parkinson's disease (PD) were assessed. In situ proximity ligation assays (PLA) identified AT<sub>1</sub>CB<sub>1</sub>Hets in neurons, in which an important finding was that Ca<sup>2+</sup> level increase upon AT<sub>1</sub>R activation was reduced in the presence of cannabinoids acting on CB<sub>1</sub>Rs. AT<sub>1</sub>CB<sub>1</sub>Het expression was quantified in samples from the 6-hydroxydopamine (6-OHDA) hemilesioned rat model of PD in which a lower expression of AT<sub>1</sub>CB<sub>1</sub>Hets was observed in striatal neurons from lesioned animals (versus non-lesioned). AT<sub>1</sub>CB<sub>1</sub>Het expression changed depending on both the lesion and the consequences of levodopa administration, i.e., dyskinesias versus lack of involuntary movements. A partial recovery in AT<sub>1</sub>CB<sub>1</sub>Het expression was detected in lesioned animals that developed levodopa-induced dyskinesias. These findings support the existence of a compensatory mechanism mediated by AT<sub>1</sub>CB<sub>1</sub>Hets that modulates susceptibility to levodopa-induced dyskinesias in PD. Therefore, cannabinoids may be useful in reducing calcium dyshomeostasis in dyskinesia.
Authors
- José L. Labandeira‐García (ORCID: https://orcid.org/0000-0002-8243-9791)
- Ana Muñoz (ORCID: https://orcid.org/0000-0002-7214-9774)
- Gemma Navarro (ORCID: https://orcid.org/0000-0003-4654-0873)
- Iu Raïch (ORCID: https://orcid.org/0000-0001-6271-0495)
- Rafael Rivas‐Santisteban (ORCID: https://orcid.org/0000-0002-2078-6819)
- Rafael Franco (ORCID: https://orcid.org/0000-0003-2549-4919)
- Ana I. Rodríguez‐Pérez (ORCID: https://orcid.org/0000-0003-1354-8799)
- Jaume Lillo (ORCID: https://orcid.org/0000-0001-7712-0850)
Institutions
- Universitat Autònoma de Barcelona (ES)
- Universidade de Santiago de Compostela (ES)
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- Center for Research in Molecular Medicine and Chronic Diseases (ES)
- Institut de Biologia Molecular de Barcelona (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- npj Parkinson s Disease
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1038/s41531-024-00827-7
- Citations
- 5
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 2.24
Funders
- European Commission
- Universitat de Barcelona
- European Regional Development Fund
- Agencia Estatal de Investigación